In order to meet the needs of researchers and provide a world-class infrastructure, Total Cancer Care has developed an innovative business model that includes research partnerships with research centers, academic institutions and industry. For example, an active research collaboration with Merck & Co. is leading to the development of personalized cancer treatments for patients using molecular technology.
M2Gen was formed to manage the Total Cancer Care Study across all consortium members and research partners. M2Gen is a wholly owned subsidiary of Moffitt Cancer Center and is responsible for the tissue collection from patients enrolled on the Total Cancer Care Study and the related Total Cancer Care database. M2Gen analyzes these tissue samples to identify the biological markers unique to each tumor. Analyzing patients’ responses to specific treatments will lead to more individualized care aimed at providing rapid improvement with fewer side effects.